27/08/2026 AbbVie submitted a regulatory application to the EMA for SC induction dosing of risankizumab in adults with moderately to severely active CD TEZSPIRE® demonstrated positive phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Argenx completed the acquisition of Forte Biosciences Priovant announced the US FDA approval of brepocitinib for adults with dermatomyositis AbbVie submitted a regulatory application to the EMA for